Vizsgálati helyszín
Hopital Huriez
Lille Cedex, 59045, FranciaországMég nincs intézményhez kötve
- 15futó vizsgálat
- 7lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 22 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis12 vizsgálat
- 2. fázis9 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz8 vizsgálat
- Lezárult7 vizsgálat
- Toboroz6 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Centre Hospitalier Universitaire De Nantes2 vizsgálat
- Novartis Pharmaceuticals2 vizsgálat
- University Hospital, Rouen2 vizsgálat
- Amgen1 vizsgálat
- Arcus Biosciences, Inc.1 vizsgálat
- és még 14
Futó vizsgálatok
Fut, nem toboroz
Prospective multicenter randomized controlled double-blind label study of the prophylaxis of recurrent pouchitis after fecal microbiota transplant in UC with ileo-anal anastomosis.
NCT03524352· 3. fázis· Centre Hospitalier Universitaire De Nantes· Forrás
Még nem toboroz
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
2025-521090-14-00· 2. fázis· Assistance Publique Hopitaux De Paris· Forrás
Toboroz
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155· 2. fázis· argenx· Forrás
Fut, nem toboroz
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines
2023-505739-12-01· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357· 3. fázis· AstraZeneca· Forrás
Toboroz
Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy
NCT06107920· 3. fázis· University Hospital, Rouen· Forrás
Toboroz
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma
2023-503206-37-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Fut, nem toboroz
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busulfan versus fludarabine/busulfan) in adults with acute myeloid leukemia and eligible to allogeneic stem cell transplantation: a SFGM-TC study
2022-502019-12-00· 3. fázis· Centre Hospitalier Universitaire De Nantes· Forrás
Fut, nem toboroz
MSI/dMMR tumors in perioperative setting
NCT04795661· 2. fázis· Centre Leon Berard· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136· 2. fázis· Mirum Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma
NCT04561492· 2. fázis· Nantes University Hospital· Forrás
Fut, nem toboroz
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497· 3. fázis· Amgen· Forrás
Toboroz
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
NCT04325425· 2. fázis· Centre Hospitalier Universitaire Dijon· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Még nem toboroz
Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
NCT05651880· 3. fázis· University Hospital, Rouen· Forrás
Fut, nem toboroz
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
NCT06246643· 2. fázis· Bayer· Forrás
Lezárult
A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
NCT04781543· 2. fázis· Horizon Therapeutics Ireland Designated Activity Company· Forrás
Lezárult
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
NCT05568095· 3. fázis· Arcus Biosciences, Inc.· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696· 2. fázis· Beeline Medicines Corporation· Forrás
Lezárult
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
NCT04930094· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
ROLLOVER STUDY FOR TAZEMETOSTAT
NCT02875548· 1/2. fázis· Epizyme Inc.· Forrás
Hibát jelzek